These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22188557)

  • 21. The effects of skin-to-skin contact, application site washing, and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray.
    Schumacher RJ; Gattermeir DJ; Peterson CA; Wisdom C; Day WW
    Menopause; 2009; 16(1):177-83. PubMed ID: 18779758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation.
    Rolf C; Knie U; Lemmnitz G; Nieschlag E
    Clin Endocrinol (Oxf); 2002 May; 56(5):637-41. PubMed ID: 12030915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.
    Muram D; Melby T; Alles Kingshill E
    Curr Med Res Opin; 2012 May; 28(5):761-6. PubMed ID: 22458919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
    Cunningham G; Belkoff L; Brock G; Efros M; Gittelman M; Carrara D; Neijber A; Ando M; Mitchel J
    Endocr Pract; 2017 May; 23(5):557-565. PubMed ID: 28225313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
    Dinsmore WW; Wyllie MG
    BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
    Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
    Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus.
    Javanbakht M; Singh AB; Mazer NA; Beall G; Sinha-Hikim I; Shen R; Bhasin S
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2395-401. PubMed ID: 10902784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants.
    Kelleher S; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):531-6. PubMed ID: 11678837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies.
    Efros M; Carrara D; Neijber A
    Andrologia; 2016 Aug; 48(6):637-45. PubMed ID: 26598279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testim 1% testosterone gel for the treatment of male hypogonadism.
    Bouloux P
    Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application site affects the pharmacokinetics of topical testosterone applied to the axilla compared with the inner arm.
    Davis SR; Evans AM; Humberstone A
    Clin Ther; 2014 Oct; 36(10):1395-401. PubMed ID: 25073836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies.
    de Ronde W
    Hum Reprod; 2009 Feb; 24(2):425-8. PubMed ID: 18948313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of a testosterone gel in healthy postmenopausal women.
    Singh AB; Lee ML; Sinha-Hikim I; Kushnir M; Meikle W; Rockwood A; Afework S; Bhasin S
    J Clin Endocrinol Metab; 2006 Jan; 91(1):136-44. PubMed ID: 16263817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.